Teva Welcomes Potential For Olanzapine ‘Running Start’ Amid Positive Clinical Data
No New Safety Signals Identified And No PDSS Events Reported To-Date, Initial Data Shows
Buoyed by the success of its long-acting risperidone injectable, Teva is continuing to feel upbeat about the potential for its olanzapine LAI candidate, ahead of a full study safety readout anticipated in the first half of 2025.
